NCT06320717View on ClinicalTrials.gov

AI Derived Biomarker to Select Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma

RecruitingOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

January 2, 2024

Primary Completion Date

July 2, 2026

Study Completion Date

July 2, 2026

Conditions
Pancreatic Ductal Adenocarcinoma
Interventions
OTHER

Blood sample

To determine if there are any biomarkers in the blood that could be used to choose best treatment plan for future patients

Trial Locations (2)

11795

RECRUITING

Good Samaritan University Hospital, West Islip

14263

RECRUITING

Roswell Park Comprehensive Cancer Center, Buffalo

All Listed Sponsors
lead

Roswell Park Cancer Institute

OTHER